Nanoparticle-Based Bioaffinity Assays: From the Research
Laboratory to the Market

J 2024

Nanoparticle-Based Bioaffinity Assays: From the Research Laboratory to the Market

FARKA, Zdeněk; Julian BRANDMEIER; Matthias Jürgen MICKERT; Matěj PASTUCHA; Karel LACINA et al.

Základní údaje

Originální název

Nanoparticle-Based Bioaffinity Assays: From the Research Laboratory to the Market

Autoři

FARKA, Zdeněk; Julian BRANDMEIER; Matthias Jürgen MICKERT; Matěj PASTUCHA; Karel LACINA; Petr SKLÁDAL; Tero SOUKKA a Hans-Heiner GORRIS

Vydání

Advanced Materials, Weinheim, Wiley-VCH, 2024, 0935-9648

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10406 Analytical chemistry

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 26.800

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/24:00139351

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

bioaffinity assay; immunoassay; nanoparticle; nanomaterial; commercialization

Štítky

14313050, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 6. 2025 12:38, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Advances in the development of new biorecognition elements, nanoparticle-based labels as well as instrumentation have inspired the design of new bioaffinity assays. This review critically discusses the potential of nanoparticles to replace current enzymatic or molecular labels in immunoassays and other bioaffinity assays. Successful implementations of nanoparticles in commercial assays and the need for rapid tests incorporating nanoparticles in different roles such as capture support, signal generation elements, and signal amplification systems are highlighted. The limited number of nanoparticles applied in current commercial assays can be explained by challenges associated with the analysis of real samples (e.g., blood, urine, or nasal swabs) that are difficult to resolve, particularly if the same performance can be achieved more easily by conventional labels. Lateral flow assays that are based on the visual detection of the red-colored line formed by colloidal gold are a notable exception, exemplified by SARS-CoV-2 rapid antigen tests that have moved from initial laboratory testing to widespread market adaption in less than two years.

Návaznosti

GF23-06199K, projekt VaV

Název: Nové anti-Stokesové lanthanoidové nanočástice a vícebarevný FRET mechanismy pro jednomolekulové sekvenování DNA

Investor: Grantová agentura ČR, Nové anti-Stokesové upkonverzní nanočástice a vícebarevný FRET pro jednomolekulové sekvenování DNA, Lead agentura

Citovat

FARKA, Zdeněk; Julian BRANDMEIER; Matthias Jürgen MICKERT; Matěj PASTUCHA; Karel LACINA; Petr SKLÁDAL; Tero SOUKKA a Hans-Heiner GORRIS. Nanoparticle-Based Bioaffinity Assays: From the Research Laboratory to the Market. Advanced Materials. Weinheim: Wiley-VCH, 2024, roč. 36, č. 3, s. 1-23. ISSN 0935-9648. Dostupné z: https://doi.org/10.1002/adma.202307653.

@article{2366078,
   author = {Farka, Zdeněk and Brandmeier, Julian and Mickert, Matthias Jürgen and Pastucha, Matěj and Lacina, Karel and Skládal, Petr and Soukka, Tero and Gorris, HansandHeiner},
   article_location = {Weinheim},
   article_number = {3},
   doi = {https://doi.org/10.1002/adma.202307653},
   keywords = {bioaffinity assay; immunoassay; nanoparticle; nanomaterial; commercialization},
   language = {eng},
   issn = {0935-9648},
   journal = {Advanced Materials},
   title = {Nanoparticle-Based Bioaffinity Assays: From the Research Laboratory to the Market},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/adma.202307653},
   volume = {36},
   year = {2024}
}

TY  - JOUR
ID  - 2366078
AU  - Farka, Zdeněk - Brandmeier, Julian - Mickert, Matthias Jürgen - Pastucha, Matěj - Lacina, Karel - Skládal, Petr - Soukka, Tero - Gorris, Hans-Heiner
PY  - 2024
TI  - Nanoparticle-Based Bioaffinity Assays: From the Research Laboratory to the Market
JF  - Advanced Materials
VL  - 36
IS  - 3
SP  - 1-23
EP  - 1-23
PB  - Wiley-VCH
SN  - 09359648
KW  - bioaffinity assay
KW  - immunoassay
KW  - nanoparticle
KW  - nanomaterial
KW  - commercialization
UR  - https://onlinelibrary.wiley.com/doi/10.1002/adma.202307653
N2  - Advances in the development of new biorecognition elements, nanoparticle-based labels as well as instrumentation have inspired the design of new bioaffinity assays. This review critically discusses the potential of nanoparticles to replace current enzymatic or molecular labels in immunoassays and other bioaffinity assays. Successful implementations of nanoparticles in commercial assays and the need for rapid tests incorporating nanoparticles in different roles such as capture support, signal generation elements, and signal amplification systems are highlighted. The limited number of nanoparticles applied in current commercial assays can be explained by challenges associated with the analysis of real samples (e.g., blood, urine, or nasal swabs) that are difficult to resolve, particularly if the same performance can be achieved more easily by conventional labels. Lateral flow assays that are based on the visual detection of the red-colored line formed by colloidal gold are a notable exception, exemplified by SARS-CoV-2 rapid antigen tests that have moved from initial laboratory testing to widespread market adaption in less than two years.
ER  -

FARKA, Zdeněk; Julian BRANDMEIER; Matthias Jürgen MICKERT; Matěj PASTUCHA; Karel LACINA; Petr SKLÁDAL; Tero SOUKKA a Hans-Heiner GORRIS. Nanoparticle-Based Bioaffinity Assays: From the Research Laboratory to the Market. \textit{Advanced Materials}. Weinheim: Wiley-VCH, 2024, roč.~36, č.~3, s.~1-23. ISSN~0935-9648. Dostupné z: https://doi.org/10.1002/adma.202307653.

Přehled o publikaci